Literature DB >> 27537099

Equipoise is necessary for randomising patients to clinical trials.

Gorm Greisen1, Frank van Bel2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27537099     DOI： 10.1111/apa.13549

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN： 0803-5253            Impact factor:   2.299


× No keyword cloud information.
  4 in total

1.  A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era.

Authors:  Jinhee Lee; Han Wul Shin; Jun Young Lee; Jae Seok Kim; Jae Won Yang; Keum Hwa Lee; Andreas Kronbichler; Jae Il Shin
Journal:  Medicina (Kaunas)       Date:  2020-06-26       Impact factor: 2.430

2.  Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?

Authors:  Petra C E Hissink Muller; Bahar Yildiz; Cornelia F Allaart; Danielle M C Brinkman; Marion van Rossum; Lisette W A van Suijlekom-Smit; J Merlijn van den Berg; Rebecca Ten Cate; Martine C de Vries
Journal:  BMC Med Ethics       Date:  2018-12-20       Impact factor: 2.652

3.  Cerebral Oximetry in Preterm Infants-To Use or Not to Use, That Is the Question.

Authors:  Gorm Greisen; Mathias Lühr Hansen; Marie Isabel Skov Rasmussen; Maria Vestager; Simon Hyttel-Sørensen; Gitte Holst Hahn
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418

4.  Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial.

Authors:  Mathias Lühr Hansen; Adelina Pellicer; Christian Gluud; Eugene Dempsey; Jonathan Mintzer; Simon Hyttel-Sørensen; Anne Marie Heuchan; Cornelia Hagmann; Ebru Ergenekon; Gabriel Dimitriou; Gerhard Pichler; Gunnar Naulaers; Guoqiang Cheng; Hercilia Guimarães; Jakub Tkaczyk; Karen B Kreutzer; Monica Fumagalli; Olivier Claris; Petra Lemmers; Siv Fredly; Tomasz Szczapa; Topun Austin; Janus Christian Jakobsen; Gorm Greisen
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.